Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
grade A 104.75 -1.42% -1.51
GLPG closed down 1.42 percent on Friday, January 18, 2019, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical GLPG trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction -1.42%
Jan 17 Stochastic Reached Overbought Strength -1.42%
Jan 17 Overbought Stochastic Strength -1.42%
Jan 17 Up 3 Days in a Row Strength -1.42%
Jan 16 Narrow Range Bar Range Contraction 0.38%
Jan 16 NR7 Range Contraction 0.38%
Jan 16 Gapped Up Strength 0.38%

Older signals for GLPG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Is GLPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 122.28
52 Week Low 85.0
Average Volume 98,474
200-Day Moving Average 101.3922
50-Day Moving Average 100.4762
20-Day Moving Average 97.5435
10-Day Moving Average 103.883
Average True Range 3.395
ADX 18.52
+DI 35.2157
-DI 24.305
Chandelier Exit (Long, 3 ATRs ) 96.705
Chandelier Exit (Short, 3 ATRs ) 95.185
Upper Bollinger Band 111.2001
Lower Bollinger Band 83.8869
Percent B (%b) 0.76
BandWidth 28.001046
MACD Line 1.6975
MACD Signal Line 0.5761
MACD Histogram 1.1215
Fundamentals Value
Market Cap 5.33 Billion
Num Shares 50.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -149.64
Price-to-Sales 23.11
Price-to-Book 3.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 106.14
Resistance 3 (R3) 106.14 105.68 105.91
Resistance 2 (R2) 105.68 105.32 105.68 105.83
Resistance 1 (R1) 105.21 105.11 104.98 105.21 105.75
Pivot Point 104.75 104.75 104.64 104.75 104.75
Support 1 (S1) 104.29 104.40 104.06 104.29 103.75
Support 2 (S2) 103.83 104.18 103.83 103.67
Support 3 (S3) 103.36 103.83 103.59
Support 4 (S4) 103.36